Vohra Prerna, Chintoan-Uta Cosmin, Terra Vanessa S, Bremner Abi, Cuccui Jon, Wren Brendan W, Vervelde Lonneke, Stevens Mark P
The Roslin Institute and Royal (Dick) School of Veterinary Studies, University of Edinburgh, Edinburgh EH25 9RG, UK.
Institute for Immunology and Infection Research, School of Biological Sciences, Charlotte Auerbach Road, University of Edinburgh, Edinburgh EH9 3FL, UK.
Vaccines (Basel). 2020 Sep 11;8(3):520. doi: 10.3390/vaccines8030520.
is the leading bacterial cause of human gastroenteritis worldwide and the handling or consumption of contaminated poultry meat is the key source of infection. proteins FlpA and SodB and glycoconjugates containing the -glycan have been separately reported to be partially protective vaccines in chickens. In this study, two novel glycoproteins generated by protein glycan coupling technology-G-FlpA and G-SodB (with two and three -glycosylation sites, respectively)-were evaluated for efficacy against intestinal colonisation of chickens by strain M1 relative to their unglycosylated variants. Two independent trials of the same design were performed with either a high challenge dose of 10 colony-forming units (CFU) or a minimum challenge dose of 10 CFU of M1. While antigen-specific serum IgY was detected in both trials, no reduction in caecal colonisation by M1 was observed and glycosylation of vaccine antigens had no effect on the outcome. Our data highlight inconsistencies in the outcome of vaccination trials that may reflect antigen-, challenge strain-, vaccine administration-, adjuvant- and chicken line-specific differences from previously published studies. Refinement of glycoconjugate vaccines by increasing glycosylation levels or using highly immunogenic protein carriers could improve their efficacy.
是全球人类肠胃炎的主要细菌病因,处理或食用受污染的禽肉是主要感染源。蛋白质FlpA和SodB以及含有β-聚糖的糖缀合物已分别被报道为鸡的部分保护性疫苗。在本研究中,评估了通过蛋白质-聚糖偶联技术产生的两种新型糖蛋白——G-FlpA和G-SodB(分别具有两个和三个β-糖基化位点)相对于其未糖基化变体对鸡肠道中M1菌株定植的抵抗效果。采用相同设计进行了两项独立试验,分别使用10⁸菌落形成单位(CFU)的高攻毒剂量或10³CFU的M1最低攻毒剂量。虽然在两项试验中均检测到了抗原特异性血清IgY,但未观察到M1在盲肠定植的减少,疫苗抗原的糖基化对结果没有影响。我们的数据突出了疫苗接种试验结果的不一致性,这可能反映了与先前发表的研究相比,在抗原、攻毒株、疫苗接种、佐剂和鸡品系方面的差异。通过提高糖基化水平或使用高免疫原性蛋白质载体来优化糖缀合物疫苗可能会提高其效力。